Home » Clinical Trials » Leukemia » NCT04546906
NCT04546906

Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

Study Summary

This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD22 CAR-T cell in the treatment of recurrent or refractory B-ALL

Want to learn more about this trial?

Request More Info

Interventions

CD22 CAR-TBIOLOGICAL
Biological: CD22 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis

Study Locations

FacilityCityStateCountry
Hebei yanda Ludaopei HospitalHeibeiSanheChina
BeiJing Ludaopei HospitalBeijingYizhuangChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026